A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder
Engelsk titel: A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder
Läs online
Författare:
Ghanizadeh, Ahmad
Email: ghanizad@sina.tums.ac.ir
Språk: Eng
Antal referenser: 36
Dokumenttyp:
Systematisk översikt
UI-nummer: 15063874
Sammanfattning
Background: No published systematic review has ever assessed the efficacy and safety of
reboxetine for treating of patients with attention deficit hyperactivity disorder (ADHD). Aim: This
systematic review aimed to review the available evidence regarding the efficacy of reboxetine for
treating ADHD. Method: The databases of Pubmed/Medline, Google scholar, SCOPUS and Web of
Science were searched using the Keywords: "reboxetine", "ADHD" and "attention deficit hyperactivity
disorder". The reference lists of the included studies were screened to find any possible other
relevant articles. All the non-controlled and controlled clinical trials were included. Results: The
current evidence mainly consists of un-controlled studies, such as case series. Only three of 33
studies were controlled clinical trials. They are from single sites and included a sub-sample of
patients with ADHD. Conclusion: Non-controlled studies and controlled trials support the promising
effect of reboxetine for treating ADHD in a sub-sample of patients that are without co-morbid
psychiatric disorder and mental retardation. Reboxetine is tolerated well. However, more controlled
trials are needed to reach any firm conclusion.